Efficacy and safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly compared to tirzepatide 15 mg s.c. once-weekly in participants with obesity
Description
Subjects will be randomly assigned to study medication and receive dietary counseling and be followed over 78 weeks.
Details
Age
Adult
Eligibility
-male or female -age 18 or older -BMI > or = to 30 -Not have type 1 or type 2 diabetes
Type of Study
Treatment
Locations
Anschutz Health and Wellness
Outpatient CTRC
Principal Investigator
Daniel Bessesen, MD
Study ID
Protocol Number: 23-1695
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers